Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool February 4, 2008 Brian Lawler	Best International Stock: Novo Nordisk A quick summary of Danish drugmaker Novo Nordisk, the world's number one manufacturer of diabetes medications.
Chemistry World September 24, 2012 Andrew Turley	$100m of diabetes R&D in China Danish drug maker Novo Nordisk has announced plans to invest $100 million in its R&D site in Beijing, China. The move will create 130 -- 200 new research jobs.
BusinessWeek April 30, 2010 Drew Armstrong	The Lobbying for Death by Diabetes How a health-reform provision may help spur sales of insulin.
Pharmaceutical Executive January 1, 2006 Gina Ashe	Alternative Media: Patient Bloggers on Your Brands Find out what patient bloggers are saying about your pharmaceutical brands.
Pharmaceutical Executive November 1, 2014 William Looney	Dane in America Jesper Hoiland, Novo Nordisk's President for North America, assesses the challenges and opportunities during his first year at the helm of the diabetes franchise leader's biggest affiliate market.
Pharmaceutical Executive February 1, 2006 Elizabeth A. Browning	Direct to Consumer: Women Are a Powerful, But Untapped, Audience Pharmaceutical marketers should seize the opportunity to reach out to women, who are an information-seeking, receptive audience.
Pharmaceutical Executive December 1, 2010 Sandra Stahl	Gentle Collisions in Marketing Healthcare marketing in today's post-recession economy is not about one-size-fits-all vehicles, but rather about bringing your product into consumers' lives in a series of personal, non-invasive ways
The Motley Fool August 12, 2005 Stephen D. Simpson	Novo Nordisk Perks Up This leading insulin company rebounds from a sluggish first quarter. For investors willing to buy and hold a stock for years, Novo Nordisk could still be an interesting play on a serious and growing disease market.
The Motley Fool January 28, 2005 Stephen D. Simpson	An Understated Scandinavian The Danish pharmaceutical may not be quite cheap enough to be a true value, but investors looking for a solid growth stock should see what's new with Novo Nordisk.
Pharmaceutical Executive April 1, 2006 Howard Steinberg	Alternative Media: TV's Targeted Comeback Educational TV programming provides a new channel of information for disease sufferers.
Pharmaceutical Executive October 1, 2005	Changing Diabetes An interview with Novo Nordisk's president of U.S. operations Martin Soeters on how a nation that leads the world in diabetes research does such a poor job of treating it. Here, he offers some solutions.
The Motley Fool January 31, 2007 Brian Lawler	Novo Nordisk Knows Sales Growth Diabetes care leads the way for this Danish drugmaker. Investors willing to do a little extra financial sleuthing will find a pharmaceutical company that's the global leader in a rapidly growing health-care segment.
Chemistry World June 16, 2014 Phillip Broadwith	Novo Nordisk to create 6000 jobs by 2022 Danish insulin and diabetes specialist Novo Nordisk says it intends to employ 6000 more highly skilled workers within Denmark by 2022. Half of these new staff will work in R&D.
The Motley Fool November 5, 2007 Brian Lawler	Follow the Trend With Novo Nordisk The future is bright for Danish drugmaker Novo Nordisk. The worldwide leader in diabetes treatments turns in another good quarter.
The Motley Fool October 31, 2006 Brian Lawler	Novo Nordisk Still Knows Sales There's more competition in diabetes care now, but the Danish pharmaceutical is thriving. Investors, take note.
Nursing Management January 2012 Lawrence et al.	Type 2 Diabetes: Growing to Epic Proportions Affecting all age groups and all aspects of a person's life, diabetes is a major public health issue worldwide, requiring lifelong behavioral and lifestyle changes and support.
The Motley Fool September 30, 2008 Brian Lawler	Novo Nordisk Takes On All Comers Its diabetes franchise is about to get bigger.
AskMen.com April 29, 2001 Joshua Levine	Do You Have Diabetes? Diabetes is not contagious; people cannot "catch" it from one another. However, certain factors can increase one's risk of developing the disease...
Chemistry World November 9, 2010 Andrew Turley	Company snapshot: Novo Nordisk As the results for the third quarter of this year roll in, one pharma major - Danish company Novo Nordisk - seems to have done better than most with its diabetes medicines.
The Motley Fool June 27, 2008 Brian Lawler	This Drug Market Is Booming One therapeutic category seems to be expanding significantly faster than most of its peers, the one that helps the unfortunately burgeoning number of diabetics in the U.S. and worldwide.
The Motley Fool June 30, 2011 David Williamson	Biotech Takes On the Next Big Problem The news coming out of this week's annual conference of the American Diabetes Association wasn't good.
HBS Working Knowledge November 17, 2003 Martha Lagace	The Business Case for Diabetes Disease Management Diabetes is a tough disease to tackle. A case-study discussion led by Harvard professor Nancy Beaulieu asked why it is so complex for business and society, and what might be done to curb its incidence.
The Motley Fool August 21, 2007 Brian Orelli	Sweet Phase 3 Data Although diabetes drugs have come under fire lately, insulin maker Novo Nordisk is moving full steam ahead with its newest drug to help fight type 2 diabetes.
Chemistry World September 3, 2014 Phillip Broadwith	Novo Nordisk quits inflammation R&D and cuts jobs Novo Nordisk is terminating its inflammatory disease R&D programs after the company's leading rheumatoid arthritis drug candidate failed in clinical trials.
The Motley Fool November 24, 2010 Brian Orelli	Profit From the United States of Diabetes Half the country could have an early form by 2020.
Pharmaceutical Executive September 1, 2011	Pharma and Social Media: Ready to Make Nice? The time is right for industry to overcome its social media phobia once and for all.
The Motley Fool June 24, 2008 Brian Orelli	A Diabetes Drug Delivery Deal Several pharmaceutical companies compete to deliver a diabetes medication that can be taken orally or once-weekly.
Pharmaceutical Executive March 1, 2013 Ben Comer	Brand of the Year: Januvia When Merck's Januvia received its first regulatory approval, in Mexico in 2006, no one predicted its long-term success. In 2012, the company's diabetes franchise became the highest-selling product family in Merck's 122-year history.
The Motley Fool October 27, 2005 Stephen D. Simpson	What's New With Novo? Novo Nordisk is a good play on diabetes, but will new drugs reduce the need for insulin? Investors, take note.
The Motley Fool September 30, 2011 Brian Orelli	A Drug Market That's 366 Million Strong Diabetes drugs have potential.
The Motley Fool August 8, 2008 Brian Lawler	Not Bad, Novo Nordisk The drugmaker's performance is better than its numbers suggest.
The Motley Fool June 9, 2008 Brian Lawler	Novo Nordisk's Daring Success Novo Nordisk's potential blockbuster compound excels in late-stage head-to-head testing. Investors, take note.
AskMen.com Alex Santoso	What You Should Know About Diabetes Not many men understand what diabetes is, why it's very bad for them (it is one of the leading causes of impotence), what they can do to avoid getting it or how to treat it.
Pharmaceutical Executive June 1, 2009 Michael Maher	Learning to Relate A multi-phase implementation strategy can debunk the myth that social media won't work for pharma.
The Motley Fool July 8, 2008 Brian Lawler	Blockbuster Drugs Bound for Extinction? One of the biggest classes of prescription drugs, those for diabetes treatments, faces tougher FDA standards.
Pharmaceutical Executive July 3, 2007 Jessica DiPaolo	Toolkit: Good Tailoring Does your marketing campaign reach the huddled masses of frustrated or illiterate healthcare consumers?
Pharmaceutical Executive August 1, 2008 Gayle Lorenzi et al.	Spanning the Treatment Gap How a diabetes field team helped docs overcome the treatment gap.
The Motley Fool November 21, 2007 Brian Orelli	Phase 2 Data to Sink Your Teeth Into Novo Nordisk releases encouraging phase 2 clinical data about its weight-loss/diabetes drug, liraglutide. Investors, take note.
American Family Physician October 15, 2003	Diabetes and Heart Disease I have diabetes -- why should I worry about heart disease?... What are the ABCs of diabetes?... Where can I learn more about diabetes and heart disease?... What can I do to reduce my risk for heart disease?
The Motley Fool April 30, 2008 Brian Lawler	A Dominating Danish Drugmaker Novo Nordisk turns in solid first-quarter financial numbers.
Managed Care May 2006 Martin Sipkoff	Health Plans Are Ill-Prepared for Looming Diabetes Epidemic The problem is outpacing insurers' resources and perhaps even their commitment. Can the chronic care model help?
American Family Physician November 1, 2000	Diabetes: How Do I Know if I Have it? Diabetes is a disease that occurs when your body doesn't make enough of a hormone called insulin, or if your body doesn't use insulin the right way. If left untreated, it may result in blindness, heart attacks, strokes, kidney failure and amputations...
American Family Physician May 1, 2001	Treatment Options for Type 2 Diabetes -- What's Available? What are the different steps in managing my diabetes? What are the different types of medicines used to treat type 2 diabetes and how do they work?
Managed Care October 2000	Diabetes Cases Up 33 Percent In Just 8 Years In findings that are likely to have serious implications for treatment-costs, adult incidence of diabetes rose 33 percent from 1990 to 1998, according to the U.S. Centers for Disease Control...
The Motley Fool September 9, 2008 Brian Orelli	Drug Duo Combines Its Way Toward an Approval Bristol-Myers and AstraZeneca are trying to get their diabetes drug approved as a combination treatment.
The Motley Fool June 28, 2010 Luke Timmerman	Orexigen Drug Shows Potential as "Two-Fer" Against Obesity and Diabetes Orexigen's latest drug aims at treating both diabetes and obesity.
American Family Physician April 15, 2004 Rao, Disraeli & Mcgregor	Impaired Glucose Tolerance and Impaired Fasting Glucose Impaired glucose tolerance and impaired fasting glucose form an intermediate stage in the natural history of diabetes mellitus.
Pharmaceutical Executive December 1, 2005 Meg Columbia-Walsh	Direct to Consumer: Culturally Relevant Marketing Through culturally relevant marketing, pharma can seamlessly weave its brands into consumers' lives... Also: The 2005 Pharmaceutical Advertising and Marketing Excellence Award recipients...
Managed Care February 2004	Improving Oral Pharmacologic Treatment And Management of Type 2 Diabetes New oral treatment options and outcome measures may help patients with type 2 diabetes to achieve better results while reducing associated costs.
The Motley Fool May 20, 2009 Brian Orelli	Joining to Treat, and Beat, Diabetes Medical-device maker Medtronic and drugmaker Eli Lilly are teaming up to co-promote the companies' diabetes products to doctors and patients.